NCT07485452 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07485452
Title	Boosting Osimertinib Blood Brain Barrier Penetration (OSIBBBOOST)
Acronym	OSIBBBOOST
Recruitment	Not yet recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Maastricht University Medical Center
Indications	lung non-small cell carcinoma
Therapies	Febuxostat + Osimertinib
Age Groups:	adult \| senior
Covered Countries	NLD

Facility	City	Country	Details
The Netherlands Cancer Institute	Amsterdam	Netherlands	Details
Maastricht UMC+	Maastricht	Netherlands	Details
Erasmus MC	Rotterdam	Netherlands	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07485452Clinical Trial Detail